Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC) Meeting Abstract
| Authors: | Owonikoko, T. K.; Borghaei, H.; Champiat, S.; Paz-Ares, L. G.; Govindan, R.; Boyer, M. J.; Johnson, M. L.; Udagawa, H.; Hummel, H. D.; Salgia, R.; Blackhall, F. H.; Boosman, R. J.; Lai, W. C. V.; Dowlati, A.; Vokes, E. E.; Hann, C. L.; Chiang, A. C.; Endraca, M.; Soman, N.; Smit, M. A. D. |
| Abstract Title: | Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC) |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368309242 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.TPS9080 |
| Notes: | Meeting Abstract: TPS9080 -- Source: Wos |
